Vaxess Technologies

Primary contact

Founded in 2012, Vaxess Technologies is developing novel vaccine formulations and delivery technologies based on its proprietary silk platform. The company is committed to improving access to vaccines by enabling better, more stable vaccine products that can be easily delivered all over the world, such as exposure to high temperatures outside of cold chain storage and transportation.
Primary contact

Funding 💰

Total $15.5M
Select investors Norwich Ventures, BioInnovation Capital, Bill & Melinda Gates Foundation, National Institutes of Health, National Science Foundation
Last update: May 13, 2018